Duloxetine: A review of its use in the management of major depressive disorder in older adults

Drugs and Aging

Volumn 30, Issue 1, 2013, Pages 59-79

  Dhillon, Sohita ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; ESCITALOPRAM; PLACEBO; TRIPTAN DERIVATIVE;

ANXIETY; AREA UNDER THE CURVE; COGNITION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; HUMAN; LIVER FAILURE; LONG TERM CARE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 84876266378     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0040-1     Document Type: Review

References (85)

1. Castro-Costa E, Dewey M, Stewart R, et al. Prevalence of depressive symptoms and syndromes in later life in ten European countries: the SHARE study. Br J Psychiatry. 2007;191:393-401.
2. Ellison JM, Kyomen HH, Harper DG. Depression in later life: an overview with treatment recommendations. Psychiatr Clin N Am. 2012;35(1):203-29.
3. Djernes JK. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand. 2006;113(5):372-87.
4. National Institutes of Mental Health. Major depressive disorder among adults. 2012. http://www.nimh.nih.gov/statistics/1MDD-ADULT.shtml. Accessed 29 Aug 2012.
5. World Health Organization. The global burden of disease: 2004 update. 2008. http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/ index.html. Accessed 29 Aug 2012.
6. Gallo JJ, Bogner HR, Morales KH, et al. Depression, cardiovascular disease, diabetes, and two-year mortality among older, primary care patients. Am J Geriatr Psychiatry. 2005;13(9):748-55.
7. Blazer DG 2nd, Hybels CF. Origins of depression in later life. Psychol Med. 2005;35(9):1241-52.
8. Sheline YI, Pieper CF, Barch DM, et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry. 2010;67(3):277-85.
9. Disabato BM, Sheline YI. Biological basis of late life depression. Curr Psychiatry Rep. 2012;14(4):273-9.
10. Sexton CE, McDermott L, Kalu UG, et al. Exploring the pattern and neural correlates of neuropsychological impairment in late-life depression. Psychol Med. 2012;42(6):1195-202.
11. Alexopoulos GS, Morimoto SS. The inflammation hypothesis in geriatric depression. Int J Geriatr Psychiatry. 2011;26(11):1109-18.
12. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol (Oxf). 2008;22(4):343-96.
13. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. 2010. http://psychiatryonline. org/data/Books/prac/PG-Depression3rdEd.pdf. Accessed 30 Aug 2012.
14. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67-104.
15. Eli Lilly and Company. Cymbalta (duloxetine hydrochloride) delayed-release capsules: US prescribing information. 2012. http://pi.lilly.com/ us/cymbalta-pi.pdf. Accessed 19 Oct 2012.
16. European Medicines Agency. Cymbalta hard gastro-resistant capsules: summary of product characteristics. 2011. http://www.emea.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000572/WC500036781.pdf. Accessed 17 Aug 2012.
17. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007;21(7):581-609.
18. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002;8(4):361-76.
19. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27(8):1126-43.
20. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8(1):23-33.
21. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871-80.
22. Engleman EA, Perry KW, Mayle DA, et al. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 1995;12(4):287-95.
23. Kasamo K, Blier P, De Montigny C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther. 1996;277(1):278-86.
24. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24(5):511-21.
25. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28(9):1685-93.
26. Derby MA, Zhang L, Chappell JC, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol. 2007;49(6):384-93.
27. Chappell J, He J, Knadler MP, et al. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol. 2009;49(12):1456-66.
28. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol. 2004;57(1):54-61.
29. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40(2):161-7.
30. Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281-94.
31. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31(9):1142-50.
32. Lobo ED, Quinlan T, O'Brien L, et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation [Erratum in: Clin Pharmacokinet. 2011 Oct, 50(10), pp. 687-8]. Clin Pharmacokinet. 2009;48(3):189-97.
33. Chan C, Yeo KP, Pan AX, et al. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2007;63(3):310-4.
34. Suri A, Reddy S, Gonzales C, et al. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther. 2005;43(2):78-84.
35. Lobo ED, Heathman M, Kuan HY, et al. Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Clin Pharmacokinet. 2010;49(5):311-21.
36. Lobo ED, Loghin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet. 2008;47(2):103-9.
37. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47(3):191-202.
38. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73(3):170-7.
39. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36(6):383-90.
40. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63(3):225-31.
41. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-15.
42. Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry. 2005;13(3):227-35.
43. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900-9.
44. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-23.
45. Robinson M, Oakes TM, Raskin J, et al. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry. 2012. doi: 10.1097/JGP.0b013e31825d08f1.
46. Wohlreich MM, Sullivan MD, Mallinckrodt CH, et al. Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis. Psychosomatics. 2009;50(4):402-12.
47. Raskin J, Xu JY, Kajdasz DK. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. Int Psychogeriatr. 2008;20(2):309-27.
48. Russell J, Raskin J, Wiltse C, et al. Efficacy and tolerability of duloxetine treatment in elderly patients with major depressive disorder and concurrent anxiety symptoms. Psychiatry. 2007;4(6):33-45.
49. Wise TN, Wiltse CG, Iosifescu DV, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract. 2007;61(8):1283-93.
50. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr. 2004;4:11.
51. Karp JF, Whyte EM, Lenze EJ, et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. J Clin Psychiatry. 2008;69(3):457-63.
52. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008;28(1):32-8.
53. US FDA. Urinary Retention and Urinary Hesitation: NME review follow-up. 2007. http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm103476.pdf. Accessed 23 Oct 2012.
54. National Institute for Health and Clinical Excellence. Depression: the treatment and management of depression in adults (update of NICE clinical guideline 23). 2009. http://www.nice.org.uk/CG90. Accessed 30 Aug 2012.
55. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-50.
56. Delgado PL. Neurobiology of serotonin norepinephrine reuptake inhibitors. Prim psychiatry. 2009;16(5 Suppl 4):8-15.
57. Sussman N. SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms. Prim Care Companion J Clin Psychiatry. 2003;5(Suppl 7):19-26.
58. Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther. 2010;35(2):177-88.
59. Marks DM, Shah MJ, Patkar AA, et al. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7(4):331-6.
60. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; (4):CD005454.
61. Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72(12):1660-8.
62. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. Clin Ther. 2009;31(5):945-61.
63. Mottram PG, Wilson K, Strobl JJ. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006; (1):CD003491.
64. Wiese BS. Geriatric depression: the use of antidepressants in the elderly. BCMJ. 2011;53(7):341-7.
65. Dolder C, Nelson M, Stump A. Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients. Drugs Aging. 2010;27(8):625-40.
66. Crocco EA, Castro K, Loewenstein DA. How late-life depression affects cognition: neural mechanisms. Curr Psychiatry Rep. 2010;12(1):34-8.
67. Schmitt JA, Wingen M, Ramaekers JG, et al. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12(20):2473-86.
68. Butters MA, Whyte EM, Nebes RD, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61(6):587-95.
69. Volonteri LS, Colasanti A, Cerveri G, et al. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels. J Psychopharmacol (Oxf). 2010;24(8):1193-9.
70. Kravitz RL, Ford DE. Introduction: chronic medical conditions and depression - the view from primary care. Am J Med. 2008;121(11 Suppl 2):S1-7.
71. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003;54(3):216-26.
72. Katon W, Ciechanowski P. Impact of major depression on chronic medical illness. J Psychosom Res. 2002;53(4):859-63.
73. Proctor EK, Morrow-Howell NL, Dore P, et al. Comorbid medical conditions among depressed elderly patients discharged home after acute psychiatric care. Am J Geriatr Psychiatry. 2003;11(3):329-38.
74. Mastrogiannis D, Giamouzis G, Dardiotis E, et al. Depression in patients with cardiovascular disease. Cardiol Res Pract. 2012;. doi: 10.1155/2012/794762.
75. Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, et al. Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. World J Biol Psychiatry. 2010;11(6):834-9.
76. Gallagher D, O'Regan C, Savva GM, et al. Depression, anxiety and cardiovascular disease: which symptoms are associated with increased risk in community dwelling older adults? J Affect Disord. 2012. doi: 10.1016/j.jad.2012.04.012.
77. Roose SP, Miyazaki M. Pharmacologic treatment of depression in patients with heart disease. Psychosom Med. 2005;67 Suppl 1:S54-7.
78. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14(9):796-802.
79. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768-75.
80. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25(2):132-40.
81. Kihara T, Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther. 1995;272(1):177-83.
82. Katoh A, Eigyo M, Ishibashi C, et al. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. J Pharmacol Exp Ther. 1995;272(3):1067-75.
83. Kluge M, Schussler P, Steiger A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol. 2007;17(8):527-31.
84. Chalon S, Pereira A, Lainey E, et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berlin). 2005;177(4):357-65.
85. Cardoner N, Lopez-Sola M, Pujol J, et al. Duloxetine modulates pain-related brain response in patients with major depressive disorder [abstract no. P.2.c.011]. In: 22nd Annual congress of the European College of Neuropsychopharmacology, Istanbul, 12-16 Sept 2009.